Morning Consult: Importing Foreign Price Controls Is Not the Way to Lower U.S. Drug Costs

Recently, some members of Congress and officials at the Department of Health and Human Services have championed a particular strategy to address this problem: pegging U.S. drug prices to what other countries pay for the same medicines. This op-ed, published in the Morning Consult, explains why putting our drug market at the mercy of what bureaucrats in other countries are willing to pay for lifesaving care is not the way to achieve lower drug prices. 

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin